No abstract

No abstract

metastases in multiple organs or locations. Correlations between the location, number, and SUVmax of metastatic lesions and overall survival (OS) were evaluated. Results: Of 136 patients, hepatic metastasis was found in 104, pulmonary metastasis in 36, distant lymph node metastasis in 18, peritoneal metastasis in 15, and bone metastasis in 13. The SUVmax range for metastatic lesions was 4-9.9 (mean 7.8; median 7.5). According to the sub-classification, groups I, II, and III were consisted of 35, 58, and 43 patients, respectively. The patients without bone and distant lymph node metastasis, with metastatic lesion of SUVmax <7.5, from groups I and II had significantly longer OS compared with those of the patients with bone and distant lymph node metastasis, with metastatic lesion of SUVmax 7.5, and from group III. Moreover, multivariate analysis showed that bone metastasis and higher SUVmax of metastatic lesion ( 7.5) were independent prognostic factors for OS. Conclusions: The presence of bone metastasis and high SUVmax of metastatic lesion in staging PET/CT might have prognostic value in predicting the survival of mCRC patients.

No abstract

Background: The prognostic value of Platelet-to-lymphocyte ratio (PLR) in patients with non-small-cell lung cancer (NSCLC) is still indistinct. We conducted this study to assess the prognostic significance of pretreatment PLR in patients with unresectable NSCLC.Aim of the Work: To assess the prognostic significance of pre-treatment PLR in patients with NSCLC.Material and Methods: We retrospectively reviewed 130 patients treated for NSCLC with definitive/palliative chemotherapy and/or radiotherapy in Ain-Shams Universit hospital, Clinical Oncology department between January 2014 and December 2016. Pre-treatment CBC was available for the 130 patients to calculate PLR by dividing the absolute platelet count by the absolute lymphocytic count.Results: Out of 130 patients with available pre-treatment complete blood picture, population age ranged from 23 to 87 years. Male to female ratio was 4.8:1. Adenocarcinoma presents 51% of cases. Unresectable stage II and stage III present 2% and 27% respectively, while Stage IV presents 69%. Using a cut-off value of 150, a statistically significant correlation between baseline PLR > 150 and presence of distant metastases was found (p = .043); with a trend towards less advanced stage disease among group of patients with baseline PLR < 150 (p = .064). High PLR > 150 was significantly associated with poor overall survival (OS) (median OS: 10.33 months; 95% CI: 6.23-14.42, compared to patients with PLR < 150; (median OS: 24.63 months, 95% CI:11.5-37.76, p = .008), but not PFS. In multivariate analysis, PLR < 150 was an independent good prognostic factor for OS; (HR = 0.549; 95% CI: 0.314-0.958; p = .035).Conclusion: High PLR is associated with poor OS in patients with unresectable NSCLC.